6-Mercaptopurinemonohydrate , 10mMinDMSO , 6112-76-1

Synonym(s):
6-Mercaptopurine monohydrate;6-Purinethiol;6-Thiohypoxanthine

CAS NO.：6112-76-1

Empirical Formula: C5H6N4OS

Molecular Weight: 170.19

MDL number: MFCD03854445

EINECS: 612-090-4

PRODUCT Properties

• Melting point: >300 °C(lit.)
• storage temp.: 2-8°C
• solubility: INSOLUBLE
• form: Fine Powder
• color: Yellow
• Water Solubility: INSOLUBLE
• Merck: 14,5871
• BRN: 4012091
• BCS Class: 4
• Stability: Stable. Incompatible with strong oxidizing agents, acids, strong bases. Light sensitive.

Description and Uses

6-Mercaptopurine (6-MP) is an inhibitor of purine synthesis and interconversion. It is rapidly converted to 6-mercaptopurine ribonucleoside-5''-monophosphate, which inhibits phosphoribosyl pyrophosphate (PRPP) amidotransferase, the rate-limiting enzyme in purine synthesis. It also inhibits the conversion of IMP to adenylosuccinic acid and xanthylic acid and blocks AMP formation in vitro. 6-MP (30 mg/kg) inhibits growth of sarcoma 180, adenocarcinoma E 0771, and adenocarcinoma 755 tumors and reduces the size of leukemia L1210 subcutaneous growths in mice. It also decreases delayed-type hypersensitivity and thyroid inflammation in a guinea pig model of thyroiditis when administered pre- or post-disease onset. Formulations containing mercaptopurine have been used for maintenance therapy in patients with acute lymphoblastic leukemia.

An immunosuppressive drug used to treat leukemia. It is also used for pediatric non-Hodgkin lymphoma, polycythemia vera, and psoriatic arthritis

Safety

• Symbol(GHS): GHS06,GHS08
• Signal word: Danger
• Hazard statements: H301-H341-H361fd
• Precautionary statements: P201-P202-P264-P270-P280-P301+P310
• Hazard Codes: Xn,Xi
• Risk Statements: 22-36/37/38-63-20/21/22
• Safety Statements: 22-36/37/39-45-36/37
• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 3
• RTECS: UP0400000
• HS Code: 29335995